Ziftomenib is a targeted anticancer therapy classified as a menin inhibitor, which is used to treat patients with relapsed or refractory acute myeloid leukemia (AML) harboring susceptible NPM1 mutations.… Read more
Ziftomenib is a targeted anticancer therapy classified as a menin inhibitor, which is used to treat patients with relapsed or refractory acute myeloid leukemia (AML) harboring susceptible NPM1 mutations. This category encompasses the parent drug along with its related compounds, such as the piperidine impurity and the R-enantiomer, which are essential for pharmaceutical analysis. Laboratories utilize these high-quality reference standards for rigorous impurity profiling, method validation, and quality control during oncology drug development. By providing reliable materials for techniques like HPLC and mass spectrometry, these compounds assist in identifying degradation products and ensuring chiral purity in final formulations. Access to these accurately characterized standards supports the development of precise analytical methods and maintains regulatory compliance throughout the manufacturing lifecycle of this potent therapeutic agent.